t= Aarti

corporate office; pl:h^-r-_ -

=D

Drugs Limitedl

Manufacturerc

ot: AJk Drugs A Crremicarc

?s"ryffi 1,1 ;#i: H,'i:::"'il]1 f

.,:#
ret :

022-i+oi ziig ir"i.,i #,J!^Ai:1.

3462i ri6;6;A (ru L'nes)
l!:i,o24_2107
adm
.

in

@aarridiues. com
If^?i,,!"' . {Ury, aa ft id russ. com
cIN

_.::lll

No.

Ref: ADLISE/20t6_17
Date: 12u, Augast,2076

To,
Department of Corporate
Services
BSE Limited

:urTooor.rf

igiii;iEiiisor:

National Stock Exchange of

India

Limited

Phiroze |eejeebhoy Towers,

Dalal Street,

"Exchange plaza,',
Bandra - Kurla Complex,
Bandra(E), Mumbai _ 400
051
NSE CODE: AARTIDRUGS

Mumbai - 400 001

BSE CODE _ s24s48
BSE ID - AARTIDRUGS

sub: outcome of Board Meeting

herd today i.e. r2tu August,
2016 pursuant to
Regulation 33 and Regulation
30 read with para A of part
A of schedule III
of sEBI (Listing obrigations
& Discrosure Requirements)
Regulation s,2015
Dear Sir,

Pursuant to RegulatiT 33
and Regulation 30 read with para
A of part A of schedule
III of sEBI (Listing obligatio't dDir.losure
JRequirernents) Regulations,
inform you that the Board
2015, we
of Direct<
Au sus t, 20 1 6 had in te r
- ati a.o,,,id.,u
(standalone & consotidated)
for the euarter ended 30*
June, 2016. Accordingry,
please find enclosed herewith
statement of Audited Financiar
Resurts (standarone &
Quarter ended on 30th June, 20t6 arongwith
report or the

ilt

;i,*:f.i

Jff ##rril;iiliil;

ji,

fiil*lii'il,,t;;.*"

The meeting corrmenced

at 12 noon and conclucled
at 2.30 p.m.

The above

is for your

acknowledge the receipt.

kind information and records. you

are requested to

Thanking you,
Yours faitMully,
For Aarti Drugs Limited

{,
Vibhav

S. Ranade
Company Secretary & Compliance
Officer

Encl: {,/A

Regd. Ofifice

ptot tto. N-198,

MIDC.

I6E-N
:r(TyJt:t')i
\lV*l

*'u,

=l

strr I
tff i,:'"rfr9fo";.;
*0,1 r'oustrlal
tog-o, noao Y*
"d
rvi'E"urd
t

PJot No.

-:.
--

ll=

Aarti
Drugs Liirnitedl
tlanufacturers

Zc6Z'

1rf?:,,t:
crN
No : L37o6oM;1r";4;i.'coss433

"r3rn,".,"

Or

l1cOl OHc

_:,022-.2402
Email
;-adminO"urtiO?uss.
com
: www.aarridrues.com

of : Bulk Drugs n

stotata"T

ouo,ra

Income from Operations

l1l

r'lcome rrom operarions

a sates
?Ytv
, tncome from Operations

9l-.^:^l*:

ili'^':F:"^':
\-/ .tsr ws

tax '

tt, $,ill3=r"ffino'tv

d"ri5i"*r

orat income from operations

(net)

Expenditure
(a) Cost of materials
consumed

(D, r,urchase of stock_in-trade

(cr,unnges in inventories
offinished

ro

Eli|-#,llti,"ii

and

goods,

stockin{rade

,"ihT|.,llrllil,l,lndAmorrisationExpense
ifi

be.rore other

rncome,

5i#:li*!1ffi.ons

ff

F.2l

tlt-tJ:fr

'ilXir?.:"tivitiesberorerinancecost

i:ffg:r.ru"mtivities
ttemi

arter rinance cost

(5.t

Exceptionat

ProfitfromOrdinaryActivitiesbeforeTax
0_8)
Provision for Taxation
- Cunent
- MAT Credit Entiflement
_ Earlier
vear
Frov6ion
.vvr-run for
ror uetened
Defefied Taxation
Tayarinn

iJ,T;fiT;:t"ry

Activities after

rax

(e-io)

Protit for the period

(11+1

of Profiu (Loss) of associates

Net Profit for the period
after taxes, minority interest
(ross) or associates

ltll;H;it t*u

;'::3"t#i:?i,Ttfl

i,",!9j,ff,;";";s;il!o

rtedEPs(inRs.l

5;.:,10"*":nl (t;t annuatised)

Notes:

for the quarter ended 3oth

Jun, 2016 have been reviewed
by the Audit committee
and appfoved by the Board
of Directors in their meeting
2 Company is operating as a single
herd on 12th
segment company, engaged
in phamaceutical Business.
3 Figures for the previous period
have been regrouped or
rearrangeo wnetever necessary.
4 The aforesaid Audited Financiat
www bseindia com

lff,?i;ff '*'ts

il

ffiid""::i3f#tl"'y'l;:*l^u;1"':iJffi:f,fi'::#,"'."f,:T:""""#:iiilj

g5"1;:,:ff:l5

i,ffjlji":

-",s'e

or BSE Limited

ForMRfl DRUGS,tMtrED
Place:

d^^4-

Mumbal

Dater t2th Au&st 2O1O

HARSHTT M.SAVLA

*
Regd. Office : plot No.
N_19g, MIDC, Tarapur,
Tal_palqhar.

sta

(East),
n)r ,,-.,
a,oiij?9'sion
It1Tk1-Loo
!.!;',oij;!,'fl,*t j:p:'p25 (30 Lines)
Fax
l"fumDai - 4nn ozz,

p,r^x-,

JT.MANAGING DIRECTOR

te,

gokhale B sathe
(regd.)
chartered accounl.ints
308/309, udyog mandir
no. 1,
/_c, bhagoji keer marg,
_mahim, mumbai 4OO 016.

on euarrerly
$:d_ltg{l Reporr
pursuant

_LIMITED

Srandatone Financial Results

of

to the negutaiion

SS
Disclosure Requirements)
Regulations, 20X5

AARTI DRUGS

of the SEBI (Listing Obligations

and

To
The Board of Direcrors of

AARTI DRUGS LIMITED

we have audited the quarterly standalone

financial results of AARTI DRUGS
LIMITED
('the company') for the quarter
ended June 30, 20r6,attached
herewith, being submitted
by the company pursuant to the
requirement of Regulation 33
of the sEBI (Listing

obligations and Discrosure Requirements)

Regulations, 20 I 5.

These quarterly standalone

financial results have been prepared
on the basis of the interim

financial statements, which are the

responsibility of the company,s
management. Our
responsibility is to express an opinion
on these financial results based
on our audit of such
interim financial statements, which
have been prepared in accordance
with the recognition
and measurement principles laid
down in Accounting standard (AS)
25, onlnterim
Financial Reporting, specified under
section 133 of the companies
Act, 2013 read with

Rule 7 of the companies (Accounts)

Rules, 2014 andother accounting principles
generally
accepted in India.

we conducted our audit in accordance

with the auditing standards generally accepted
in
India' Those standards require that we plan
and perform the audit to obtain reasonable

assurance about whether the financial

results are free of material misstatement(s).
An audit
includes examining, on a test basis,
evidence supporting the amounts

disclosed as financial
results' An audit also includes
assessing the accounting principles
used and significant
estimates made by management.
we believe that our audit provides a reasonable
basis for
our opinion.

tel.: (22) 43 48 42

42

fax: (24 a3 4A 42 41

office@gokhatesathe.in

gokhale

..
chartered
^,.^-.

Cd

(rwd.)

"""oun1.il

In our opinion and to the

best of our information
and according to the explaflations
given to
us these quarterly standalone
financial results:

(i)

are presented

in accordance with the requrements

of Regulation 33 of the SEBI
(Listing Obligations and Disclosure
Requirements) Regulations,
2015 in this
regard;
and

(ii)

give a true and fair view

of the net profit and other financial
information for the
quarter ended June 30, 2016.

For GOKHALE & SATHE

CHARTERED AC C OI.INTANTS

Firm Registration No.: 103264W

A&
CA TEJAS PARIKH
PARTNER
M. No. 123215
Mumbai,
Dated: August 12,2016.

sathe

gokhale

sathe
(regd.)

cnartered accour.ltants
308/30_9, udyog mandir no.

r,

Z-c, bhagoji keer marg,

mahim, mumbai 4OO 016

----Auditorts Report oD f)rro-+^_r-- ir

r4ucat'rr/
uonsolidated
LIMITED pu..uu-..
Financi"l_S.:]rs of
AARTr DRUGS
iffi
|'tl'1,'l*':*LI.:J,:orAARrrDRucs
D is
i, cl oo;s u re ti,;ffi:ff.i:.,t[:r*."-,Hil:"#
ri
n, q u i
(Lis rin g

***:}"ffiT#':"il:1y.f
;;
*-.rll
"r

""_rf;l*rilil:%

rt

;i

""

!i"r

o briga

ri on

an

To
Board of Directors
of AARTI DRUGS
LIMITED"

we have audited the quarterly

consolidated financiar
resurts of AARTI
DRuGs LIMITED

j;:;2;i,attachedherewith,beingsubmitted
[!:Hffil;]h:1'J,Tllr*:::::
obligations and Disclor"*
33 or tn. senr

il"qui*-ffffffiil:*HtTion

Girtine

These quarterly consolidated

financial results have
been prepared from
consolidated

Sf il'fi:il,,if [','ff#:il:*{:,1.i..:r""Ju'ity,llthlcompany,smanagement

ourauditorsuch"onsoroTtJ;;#riffi:,*':,"",","#lrtffi
accordance with the
recognition
standard (AS) 25'

*o -"**.-;;;;;"ciples
o" mt-** ti"*.i"r,n.qortins,'rj""in"o

;:T,i,.ffi

$,'j;,??.1i

We conducted our audit

in accordan
rndia rhos s,,*a*o,,.qui..

inui

ffi,Xff::ffirvhether

";tl

n"r.,,

the

z0

4 and o ther

tr T.,ffi. T:f;H i:ffill

?.".,rJlri:
the financialTi
results are free of materiar
misstatement(s). An
audit

resu*sAnauditi;#,1 j,',ilJJTl;J",1!lt#,,::i,li,f

:|,|ilnfade

raio Jow].in Accounting

under section r33 of

*f **i*tr;'*,1',,o.,o,n,,r

-fi

;:kf .?11#

il*il:tgf *itffi:*j

bv managemont' we
believe that our uuaj,
orouides a reasonabre basis for

we did not audit financial

statements/financiar information
rtt"t'.ti"r reflect total revenues of one subsidiary whose
of Rs.3ggl.g7 lakhs for
30' 2016 as considered in
the
the
consoridated financiar
financial statements/
statements.
financial inro*ution
These
have been r"iilo by
have been furnished
other
auditor
*r,or. report
to ut *a ou'
on the ,onronaut.d
financiar statements, in
so
o s ures in,r uo.
J in,,,p.,t or its su b
si di ary i s b as
financial statement/financial
quarter ended June

ffi

"Jrt*

*:i3','JilT;ilH:.Tj.l,'#

tet.: (22) 43 48 42

42

fax: Q2) 43 48 42 41

ed

o,ffice@gokhatesathe,in

gokhale

sathe
(regd.)

cnartered accountants

11:J#tlffifr',":::53i#i:::*::::n

us these quarterly consolidated

financial results:

(i)
(ii)

(iii)

and according to the

"*0,u,

include the quarterly financial

results of its onry subsidiary, pinnacle
Life science
Private Limited
have been presented in accordan-oe
with the requirements of Regulation
33 of the
obligations and Disclosure
R.qui'r.-.nts) Regulations, 2015
in rhis

::::iffng

give a true and fair view of

the consolidated net profit and
other financial
information for the quarter ended
June

For GOKHALE & SATHE

CHARTERED AC C OI.INTANTS
Firm Registration No.: 103264W

A,y

CA TEJAS PARIKH
PARTNER

M. No. l232ls
Place: Mumbai
Date: August 12,2016.

30, 2016.